{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:08:00Z","timestamp":1788368880247,"version":"build-2803163510"},"reference-count":34,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2019,5,23]]},"DOI":"10.3233\/jpd-181535","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T12:06:33Z","timestamp":1553256393000},"page":"351-359","source":"Crossref","is-referenced-by-count":42,"title":["Urate and Homocysteine: Predicting Motor and Cognitive Changes in Newly Diagnosed Parkinson\u2019s Disease"],"prefix":"10.1177","volume":"9","author":[{"given":"Isobel","family":"Sleeman","sequence":"first","affiliation":[{"name":"Institute of Applied Health Sciences, University of Aberdeen, UK"},{"name":"Institute of Neuroscience, Newcastle University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A.","family":"Lawson","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Yarnall","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon W.","family":"Duncan","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, UK"},{"name":"Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"Johnston","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Newcastle University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien K.","family":"Khoo","sequence":"additional","affiliation":[{"name":"School of Medicine and Menzies Health Institute Queensland, Griffith University, Australia"},{"name":"School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Burn","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Newcastle University, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-181535_ref1","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1073\/pnas.93.7.2696","article-title":"Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease","volume":"93","author":"Yoritaka","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3233\/JPD-181535_ref2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0002-9440(10)65396-5","article-title":"Parkinson\u2019s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons","volume":"154","author":"Zhang","year":"1999","journal-title":"Am J Pathol"},{"key":"10.3233\/JPD-181535_ref3","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: A hypothesis","volume":"78","author":"Ames","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3233\/JPD-181535_ref4","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/aje\/kwp033","article-title":"Plasma urate and Parkinson\u2019s disease in the atherosclerosis risk in communities (ARIC) study","volume":"169","author":"Chen","year":"2009","journal-title":"Am J Epidemiol"},{"key":"10.3233\/JPD-181535_ref5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/aje\/kwm127","article-title":"Plasma urate and risk of Parkinson\u2019s disease","volume":"166","author":"Weisskopf","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.3233\/JPD-181535_ref6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/archneur.2008.65.6.nct70003","article-title":"Serum urate as a predictor of clinical and radiographic progression in Parkinson disease","volume":"65","author":"Schwarzschild","year":"2008","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-181535_ref7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.parkreldis.2007.11.001","article-title":"Uric acid associates with cognition in Parkinson\u2019s disease","volume":"14","author":"Annanmaki","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-181535_ref8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa011613","article-title":"Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease","volume":"346","author":"Seshadri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3233\/JPD-181535_ref9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.22511","article-title":"Hyperhomocysteinemia in levodopa-treated patients with Parkinson\u2019s disease dementia","volume":"24","author":"Zoccolella","year":"2009","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181535_ref10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ageing\/aft091","article-title":"The incidence of Parkinson\u2019s disease in the North-East of England","volume":"43","author":"Duncan","year":"2014","journal-title":"Age Ageing"},{"key":"10.3233\/JPD-181535_ref11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-181535_ref12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181535_ref13","first-page":"427","article-title":"Parkinsonism: Onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"eurology"},{"key":"10.3233\/JPD-181535_ref14","doi-asserted-by":"crossref","first-page":"26492653","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181535_ref15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00050060600827599","article-title":"Accuracy of the Wechsler Test of Adult Reading (WTAR) and National Adult Reading Test (NART) when estimating IQ in a healthy Australian sample","volume":"42","author":"Mathias","year":"2007","journal-title":"Aust Psychol"},{"key":"10.3233\/JPD-181535_ref16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: A preliminary report","volume":"17","author":"Yesavage","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JPD-181535_ref17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JPD-181535_ref18","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/WNL.0b013e3181fc29c9","article-title":"The MoCA: Well-suited screen for cognitive impairment in Parkinson disease","volume":"75","author":"Dalrymple-Alford","year":"2010","journal-title":"Neurology"},{"key":"10.3233\/JPD-181535_ref19","unstructured":"(2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing [program]."},{"key":"10.3233\/JPD-181535_ref20","doi-asserted-by":"crossref","unstructured":"Bates D , M\u00e4chler M , M Bolker B , Walker S (2014)Package Lme4: Linear Mixed-Effects Models Using Eigen and S4.","DOI":"10.18637\/jss.v067.i01"},{"key":"10.3233\/JPD-181535_ref21","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archneurol.2009.247","article-title":"Urate as a predictor of the rate of clinical decline in Parkinson disease","volume":"66","author":"Ascherio","year":"2009","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-181535_ref22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1073\/pnas.1217296110","article-title":"Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegenera-tion","volume":"110","author":"Chen","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3233\/JPD-181535_ref23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/mds.26483","article-title":"Oral inosine persistently elevates plasma antioxidant capacity in Parkinson\u2019s disease","volume":"31","author":"Bhattacharyya","year":"2016","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181535_ref24","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/mds.22522","article-title":"Homocys-teine and cognitive impairment in Parkinson\u2019s disease: A biochemical, neuroimaging, and genetic study","volume":"24","author":"Rodriguez-Oroz","year":"2009","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181535_ref25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","article-title":"Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associations","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-181535_ref26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-007-0336-0","article-title":"Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson\u2019s disease patients","volume":"115","author":"Lashley","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JPD-181535_ref27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/mds.21997","article-title":"Rivastigmine versus placebo in hyperhomocysteine-mic Parkinson\u2019s disease dementia patients","volume":"23","author":"Barone","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-181535_ref28","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.159.10.1077","article-title":"Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women","volume":"159","author":"Bostom","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.3233\/JPD-181535_ref29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1471-4159.2009.06207.x","article-title":"Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death","volume":"110","author":"Poddar","year":"2009","journal-title":"J Neurochem"},{"key":"10.3233\/JPD-181535_ref30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","article-title":"Charlton CG (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents","volume":"26","author":"Lee","journal-title":"Neurotoxicology"},{"key":"10.3233\/JPD-181535_ref31","first-page":"47","article-title":"Chronic exposure of homocysteine in mice contributes to dopamine loss by enhancing oxidative stress in nigrostriatum and produces behavioral phenotypes of Parkinson\u2019s disease","volume":"6","author":"Bhattacharjee","year":"2016","journal-title":"Biochem Biophys Rep"},{"key":"10.3233\/JPD-181535_ref32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/174182670100800605","article-title":"Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies","volume":"8","author":"Clarke","year":"2001","journal-title":"J Cardiovasc Risk"},{"key":"10.3233\/JPD-181535_ref33","first-page":"9539836","article-title":"Parkinson\u2019s disease and homocysteine: A community-based study in a folate and vitamin B12 deficient population","author":"Wei","year":"2016","journal-title":"Parkinsons Dis"},{"key":"10.3233\/JPD-181535_ref34","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.parkreldis.2010.07.012","article-title":"Acute homocysteine rise after repeated levodopa application in patients with Parkinson\u2019s disease","volume":"16","author":"Muller","year":"2010","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-181535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:46:38Z","timestamp":1777610798000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-181535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":34,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jpd-181535","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]}}}